KLRG1 and PD-1 expression are increased on T-cells following tuberculosis-treatment and identify cells with different proliferative capacities in BCG-vaccinated adults

Tuberculosis (Edinb). 2016 Mar:97:163-71. doi: 10.1016/j.tube.2015.11.008. Epub 2015 Dec 8.

Abstract

In cancer and chronic infectious diseases, immune checkpoint-blockade of inhibitory receptors can enhance T-cell immunity. In tuberculosis (TB), a chronic infectious disease, prolonged antigen exposure can potentially drive terminal T-cell differentiation towards functional 'exhaustion': in human TB T-cells express PD-1 (programmed cell death protein-1) and CTLA-4 (cytotoxic T-lymphocyte-associated protein-4). However, in murine TB not PD-1 but rather killer cell lectin-like receptor subfamily-G1 (KLRG1) was a superior indicator of terminal T-cell differentiation. We therefore compared expression of KLRG1, PD-1 and CTLA-4 on T-cells in different stages of human TB, and also analysed their induction following BCG-vaccination. KLRG1, PD-1 and CTLA-4-expression were highest on in vitro BCG-stimulated CD4(+) T-cells following recent TB-treatment; KLRG1 and PD-1-expression on CD4(+) T-cells in active--but not latent--TB were only slightly increased compared to healthy donors. BCG-vaccination induced KLRG1-expression on BCG-stimulated CD8(+) but not CD4(+) T-cells, while neither PD-1 nor CTLA-4-expression increased. KLRG1-expressing CD8(+) T-cells exhibited markedly decreased proliferation, whereas PD-1(+) T-cells proliferated after in vitro BCG-stimulation. Thus, we demonstrate the presence of increased KLRG1-expressing T-cells in TB-treated individuals, and present KLRG1 as a marker of decreased human T-cell proliferation following BCG-vaccination. These results expand our understanding of cell-mediated immune control of mycobacterial infections.

Keywords: BCG-vaccination; CTLA-4; Human T-cells; Immune checkpoint-blockade; Immunity; Inhibitory receptors; KLRG1; PD-1; T-cell exhaustion; T-cells; Terminal differentiation; Tuberculosis.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Antitubercular Agents / therapeutic use*
  • BCG Vaccine / therapeutic use*
  • CTLA-4 Antigen / immunology
  • CTLA-4 Antigen / metabolism
  • Case-Control Studies
  • Cell Differentiation / drug effects
  • Cell Proliferation / drug effects*
  • Cells, Cultured
  • Female
  • Humans
  • Latent Tuberculosis / drug therapy*
  • Latent Tuberculosis / immunology
  • Latent Tuberculosis / metabolism
  • Latent Tuberculosis / microbiology
  • Lectins, C-Type / immunology
  • Lectins, C-Type / metabolism*
  • Lymphocyte Activation / drug effects
  • Male
  • Middle Aged
  • Mycobacterium tuberculosis / drug effects*
  • Mycobacterium tuberculosis / immunology
  • Mycobacterium tuberculosis / pathogenicity
  • Programmed Cell Death 1 Receptor / immunology
  • Programmed Cell Death 1 Receptor / metabolism*
  • Receptors, Immunologic
  • Remission Induction
  • T-Lymphocytes / drug effects*
  • T-Lymphocytes / immunology
  • T-Lymphocytes / metabolism
  • T-Lymphocytes / microbiology
  • Time Factors
  • Trans-Activators / immunology
  • Trans-Activators / metabolism*
  • Treatment Outcome
  • Tuberculosis, Pulmonary / drug therapy*
  • Tuberculosis, Pulmonary / immunology
  • Tuberculosis, Pulmonary / metabolism
  • Tuberculosis, Pulmonary / microbiology
  • Up-Regulation
  • Vaccination*
  • Young Adult

Substances

  • Antitubercular Agents
  • BCG Vaccine
  • CTLA-4 Antigen
  • CTLA4 protein, human
  • KLRG1 protein, human
  • Lectins, C-Type
  • PDCD1 protein, human
  • Programmed Cell Death 1 Receptor
  • Receptors, Immunologic
  • Trans-Activators